title: Saving money on the PBS: ranibizumab or bevacizumab for neovascular macular degeneration?
abstract: The cost differential between these two drugs is no longer defensible.
authors.forename: Ken J
authors.initials: KJ
authors.lastname: Harvey
authors.forename: Richard O
authors.initials: RO
authors.lastname: Day
authors.forename: William G
authors.initials: WG
authors.lastname: Campbell
authors.forename: Wendy
authors.initials: W
authors.lastname: Lipworth
mesh_terms: D020533:Angiogenesis Inhibitors / Q000191:economics* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000191:economics* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001315:Australia; D000068258:Bevacizumab; D006291:Health Policy; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy*; D009313:National Health Programs / Q000191:economics; D056687:Off-Label Use; D016032:Randomized Controlled Trials as Topic; D000069579:Ranibizumab
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D000069579:Ranibizumab